Cognition Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Cognition Therapeutics

21/03/2023 12:35

* Cognition Therapeutics Inc  CGTX.OQ   CGTX.O  is expected
to show no change in quarterly revenue when it reports 
results on March 23. 
    * 
    * ​Refinitiv's mean analyst estimate for Cognition
Therapeutics
Inc is for a loss of 22 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cognition
Therapeutics Inc is $9.5​, above​ its last closing price
of $1.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.34       -0.38      -0.29     Beat    24.5
 Jun. 30 2022  -0.29       -0.32      -0.25     Beat    22.2
 Mar. 31 2022  -0.29       -0.29      -0.17     Beat    40.7​
 Dec. 31 2021  -0.17       -0.26      -11.74    Missed  -4,424
                                                        .1
 ​​Sep.        -0.57       -0.57      -8.12     Missed  -1,324
 30 2021                                                .6
                                                        ​
 This summary was machine generated March 21 at 12:35 GMT.  All
figures in US dollars  unless otherwise stated